We’re nearly ready to use CRISPR to target far more diseases – New Scientist
New Scientist |
We’re nearly ready to use CRISPR to target far more diseases
New Scientist The race is on to edit the DNA in our body to fight or prevent disease. Promising results from animal studies targeting the liver, muscles and the brain suggest that the CRISPR genome-editing method could revolutionise medicine, allowing us to treat or … ‘CRISPR‘ Bacon: Pigs could soon save millions more livesagprofessional.com Nonviral CRISPR Delivery a SuccessThe Scientist Mammoth undertaking: CRISPR/Cas9 gene editing goes beyond medicineBioPharma-Reporter.com Guardian (blog) –wtkr.com –Scientific American all 15 news articles » |
UPI.com |
DNA mutations shed in blood predicts response to immunotherapy in patients with cancer
Science Daily “We can help predict response to immunotherapy by measuring the number of mutations in circulating tumor DNA using a simple blood test,” said Yulian Khagi, MD, UC San Diego Moores Cancer Center fellow and first author. “Immunotherapy can result in … DNA mutations in blood predict response to immunotherapyUPI.com Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from ImmunotherapyMarkets Insider |
BioPharma-Reporter.com |
CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy
BioPharma-Reporter.com According to spokeswoman Natalie de Vane, the acquisition is the first step into the cell and gene therapy space for CSL with the addition of an ex vivo hematopoietic stem cell (HSC) gene therapy candidate and R&D facilities in Pasadena, California … |
BioPharma-Reporter.com |
CGT Catapult teams with TrakCel for cell and gene therapy tracking
BioPharma-Reporter.com CGT Catapult announced its partnership with TrakCel this week, explaining the UK firm’s supply chain management platform will be used to track cell and gene therapies made at the facility and stored at an adjacent warehouse being built by Fisher … |